Targeted therapy in sarcomas other than GIST tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-Gastrointestinal Stromal Tumor (GIST) soft tissue sarcomas represent a rare and diverse category of mesenchymal tumors, accounting for less than 1% of adult malignancies.
• Current treatment paradigms largely rely on conventional cytotoxic chemotherapy.
• Recent advancements in understanding the molecular underpinnings of these tumors have paved the way for more personalized therapeutic strategies.

Purpose of the Study:

• To review the current landscape of molecularly targeted therapies for non-GIST soft tissue sarcomas.
• To highlight the clinical trial progress of inhibitors targeting key deregulated pathways, specifically angiogenesis and the cell cycle.

Main Methods:

• Literature review of preclinical and clinical studies.
• Focus on molecular inhibitors investigated in clinical trials for non-GIST soft tissue sarcomas.
• Analysis of targeted pathways including angiogenesis and cell cycle regulation.

Main Results:

• Identification of numerous molecular inhibitors targeting angiogenesis and cell cycle pathways.
• Overview of agents currently under investigation in various phases of clinical trials.
• Emerging evidence suggests potential for customized treatment approaches based on molecular profiling.

Conclusions:

• Targeted therapies offer a promising avenue beyond traditional chemotherapy for non-GIST soft tissue sarcomas.
• Inhibitors of angiogenesis and cell cycle pathways are key areas of ongoing clinical investigation.
• Further research and clinical trials are crucial to establish the efficacy and optimal use of these novel agents.